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Abstract
Mutations in the gene for calreticulin (CALR) were identiﬁed in the myeloproliferative neoplasms (MPNs) essential thrombocythaemia
(ET) and primary myeloﬁbrosis (MF) in 2013; in combination with previously described mutations in JAK2 andMPL, driver mutations
have now been described for the majority of MPN patients. In subsequent years, researchers have begun to unravel the mechanisms
by which mutant CALR drives transformation and to understand their clinical implications. Mutant CALR activates the thrombopoietin
receptor (MPL), causing constitutive activation of Janus kinase 2 (JAK2) signaling and cytokine independent growth in vitro. Mouse
models show increased numbers of hematopoietic stem cells (HSCs) and overproduction of megakaryocytic lineage cells with
associated thrombocytosis. In the clinic, detection of CALR mutations has been embedded in World Health Organization and other
international diagnostic guidelines. Distinct clinical and laboratory associations of CALRmutations have been identiﬁed together with
their prognostic signiﬁcance, with CALR mutant patients showing increased overall survival. The discovery and subsequent study of
CALR mutations have illuminated novel aspects of megakaryopoiesis and raised the possibility of new therapeutic approaches.
Introduction
In 2013, 2 seminal papers describedmutations in the calreticulin
gene (CALR) in a subset of essential thrombocythaemia (ET) or
myeloﬁbrosis (MF) patients1,2; more than 36 different mutations
were reported, all of them insertions or deletions (indels) causing a
+1 frameshift within exon 9 that generated a novel C-terminal
sequence. These mutations were mutually exclusive with Janus
kinase 2 (JAK2) and thrombopoietin receptor (MPL) mutations,
found in the majority of ET and MF patients. The two most
frequentCALRmutations, a52basepair (bp)deletion (DEL) anda
5bp insertion (INS), accounted for 85%of themutations andwere
termed type I and II, respectively (Fig. 1A). Apart from the two
most common mutations, a myriad of other mutations have been
identiﬁed. These less common mutations can be classiﬁed as either
type I-like or type II-like based on predicted helical secondary
structure3 or the number of calcium-binding amino acids
remaining in the novel C-terminus.4
While previously identiﬁed phenotypic driver mutations in
MPNs affect genes directly involved in cytokine signaling or
its regulation (eg, BCR-ABL1,5 CSF3R,6 JAK2,7–10 MPL11,12),
CALR instead encodes an endoplasmic reticulum (ER) chaperone
that serves multiple functions, including calcium homeostasis and
glycoprotein quality control, and is distributed across different
cellular compartments.13 CALR is encoded by a highly
developmentally conserved gene, with 70% nucleotide homology
between mouse and human, and has three domains: an N-
terminal lectin domain (N), a proline-rich domain (P), and an
acidic carboxyl terminus (C) that terminates in the amino acid
sequence KDEL, an ER retrieval signal.14 The N domain of
CALR is primarily responsible for its chaperone activity, while its
C domain has been identiﬁed as the major binding site of calcium
in the ER, binding Ca2+ ions with high capacity and low
afﬁnity.15 Because no truncating mutations were found in the
original patient cohorts, a gain-of-function mechanism forCALR
mutations was postulated.16
Over the past 6 years, extensive work has begun to unravel the
mechanisms underlying mutant CALR-driven transformation in
cellular systems and animal models. Clinical investigations have
started to tease out differences between CALR-positive and
negative MPNs as well as between type I and type II CALR
mutations. Finally, advances in the understanding of the
pathogenesis of CALR-driven MPNs are paving the way for a
more tailored treatment regimen for CALR-mutated patients.
Consequences of CALR mutation
Functions of mutant CALR in vitro
CALRmutations are associated with ET and MF, as are JAK2
and MPL mutations, but are mutually exclusive with JAK2
and MPL, suggesting they drive transformation through the
same pathway (some reports have found rare patients with
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co-occurring JAK2 V617F and CALR mutations, but they did
not address the possibility of biclonality17–19). Consistent with
this ﬁnding, initial experiments showed that all of these mutations
operate through the constitutive activation of the JAK2 signaling
cascade.1,2 Much of the research to date on the oncogenic effects
of CALR mutations has focused on MPL signaling in cytokine-
dependent cellular systems. CALR mutations require the
expression of MPL to render autonomous cell growth in Ba/F3
cells,20–22 UT-7/TPO cells20,23 and g2A cells expressing JAK2.24
Conversely, mutant CALR is unable to induce cytokine
independence when co-expressed with erythropoietin receptor
(EPOR)20,24 and drives little24 or no20 autonomous cell growth
upon co-expression with the granulocyte-colony stimulating
factor receptor (CSF3R). The lack of activation of EPOR by
mutant CALR likely explains why CALRmutations are not seen
in polycythemia vera (PV) patients (Fig. 1B, Fig. 2).
In order for mutant CALR to drive transformation, the
presence of the extracellular domain of MPL is required,24,25
particularly its sites for N-linked glycosylation,24 where a
lectin such as CALR would be predicted to bind. Indeed, the
glycan-binding sites of CALR itself are crucial for activating
MPL,24 while the polypeptide-binding regions and chaperone
activity of CALR are dispensable.25 Mutant CALR also requires
its novel positively charged C-terminal residues to activate MPL
signaling: mutation of these residues to uncharged glycine
residues abrogates its transforming ability.20 Of note, truncation
of exon 9 eliminates the transforming abilities of mutant CALR,
further underscoring the functional importance of the novel C-
terminus.24 Analogously, removal of the 36 most distal residues
from the new C-terminus prevents mutant CALR from trans-
forming Ba/F3-MPL cells. This D36 mutant is still able to bind to
MPL, suggesting that binding to and activation of the receptor
may be two separate processes.25 In order to activate MPL,
mutant CALR must oligomerize26; oligomerization of wild-type
CALR has also been observed when CALR is N-arginylated,27
though the N-arginylation status of mutant CALR is unknown.
Mutant CALR can only activate MPL and drive STAT5 activity
at the cell surface: if the complex is retained in the ER via
treatment with Brefeldin A, an inhibitor of ER-Golgi trafﬁcking,
no STAT5 transcriptional activity is observed. Additionally,
mutant CALR can rescue the cell surface trafﬁcking of a MPL
mutant, MPL R102P, that is normally retained in the ER in some
cases of hereditary thrombocytosis.28
Most work on mutant CALR has focused on human CALR
and MPL, but there is some evidence that analogous frameshift
mutations in murine Calr can transform g2A and Ba/F3 cells
when co-expressedwith either humanMPL or CSF3R.20,29While
the majority of studies on signaling pathways driven by mutant
CALR have used well-established cell lines, one study generated
induced pluripotent stem cell-derived hematopoietic progenitor
cell lines from a healthy donor and a patient with a type II CALR
mutation. Here, mutant CALR increased megakaryocyte num-
bers with premature commitment to megakaryopoiesis.30 Cell
lines derived from patients bearing disease-associated mutations
may thus represent promising lines of research in the future.
Though constitutive activation of the JAK2 signaling cascade is
considered the primary mechanism driving the effects of CALR
mutations, other potential mechanisms have been investigated.
CALR and JAK2mutations overlap to some extent in their ability
to activate JAK-STAT signalling31; however, additional mecha-
nisms may contribute to mutant CALR-driven oncogenesis.32
CALR mutations lead to the replacement of a series of Ca2+
-binding, negatively charged amino acids with a stretch of
positively charged residues. This would perturb the ability of
CALR to properly retain Ca2+ ions within the ER lumen, affecting
Ca2+ signaling pathways. Consistent with this idea, megakaryo-
Figure 1. A. Native and type I and type II-mutant CALR primary sequence. The frameshift (frameshifted amino acid residues in bold) within the exon 9
generates a common novel CT in cyan, which is common to all frameshift mutations and substitutes most of the native C domain, involved in the storage of calcium.
The ER retrieval signal (KDEL) is also lost. Adapted fromNangalia et al.2 B. Distribution of driver mutations inMPN. TN stands for triple negative, that is, neither JAK2,
CALR, nor MPL mutated. Adapted from Klampﬂ et al.1.
D. Prins et al. Mutant Calreticulin in the Myeloproliferative Neoplasms
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cytes derived from type I CALR-mutated patients showed an
enhanced releaseofCa2+ fromERstores compared to those derived
from either healthy donors or type II mutated patients.4 This
enhancedCa2+ signaling has been attributed to the process of store-
operated calcium entry (SOCE),which is normallymediated by the
ERCa2+ sensor STIM1.The presence ofmutantCALRdestabilizes
a complex between CALR, ERp57, and STIM1, leading to
increased SOCE and thus cell proliferation.33 Ca2+ signaling has
also been shown to regulate megakaryocyte function34 and could
therefore contribute to phenotypic differences between distinct
types of CALR mutations, as discussed further below.
It is difﬁcult to predict whether C-terminal mutations would
have a signiﬁcant structural effect on CALR as they are in a region
with a great degree of plasticity35; most structural studies of
CALR to date have focused on the more structured N-terminal
regions of the protein.36 Structural modeling analysis predicts
that the C-terminus is intrinsically disordered in both wild-type
and mutant contexts.37 Another consequence of CALR frame-
shift mutations is the loss of the C-terminal KDEL sequence,
typically responsible for ER retrieval, resulting in a shift to ER-
Golgi intermediate and Golgi compartments compared to WT
CALR.24 Mislocalized mutant CALR could therefore produce
ectopic effects. For instance, a recent report proposed that mutant
CALR interacts with the transcription factor Friend leukemia
integration-1 (FLI1) and conveys it to the nucleus, where it
regulates the MPL promoter.38 However, this may be a
consequence of enhanced JAK2 signaling rather than CALR
translocating FLI1 to the nucleus, as FLI1 has been previously
detected in the nucleus of megakaryocytes in JAK2-mutated ET
patients.39 In any case, topological analyses of subcellular
localization are complicated by the low expression of mutant
CALR protein, which is signiﬁcantly less stable than its wild-type
counterpart.22–24,40
Animal models
In addition to extensive work in cellular systems, several
groups have also developed animal models to investigate the
effects of mutant CALR. In zebraﬁsh embryos, the injection of
human type I but not type II mutant CALRmRNA resulted in an
increase in CD41+ thrombocytes and a Mpl-dependent throm-
bocytosis that was abrogated using JAK1/JAK2 inhibitors.41
Most in vivo work to date has been performed in mouse models.
In an early study using transplant of retroviral transduced bone
marrow cells into lethally irradiated mice, type I and, to a lesser
extent, type II mutantCALR produced thrombocytosis, with type
I also showing eventual progression to myeloﬁbrosis. This
phenotype was MPL-dependent and accompanied by expansion
of hematopoietic stem and progenitor cells (HSPCs) and the
megakaryocytic lineage.42 A second retroviral model of the type I
mutation showed similar results. In this case, a modest expansion
of the Lin-Sca1+cKit+ (LSK) compartment, which is enriched for
HSPCs, was observed.20 Similarly, transgenic expression of type I
mutant CALR also produced an ET-like phenotype associated
with increased numbers of HSPCs and megakaryocyte progen-
itors (MkPs), though HSPCs had no advantage in secondary
competitive transplants.43
Species-speciﬁc codon preferences mean that frameshift
deletions or insertions in the mouse locus would generate a
substantially different amino acid sequence to that seen in
patients.44 We therefore generated a mouse model in which DNA
encoding the human novel C-terminal peptide associated with the
type I mutation was knocked into the endogenous mouse Calr
locus (ie, a humanized version of the CALR mutation). This
approach yielded a hybrid protein with most of themouse protein
intact, but ending in the novel human sequence at the C-terminus,
and ensuring an appropriate level of expression under the control
of endogenous elements. This model also developed a strong ET-
like phenotype, with a two- to three-fold increase in platelet
levels, but did not progress to myeloﬁbrosis. When bred to
homozygosity, mice developed extreme thrombocytosis (platelet
counts greater than 9  106/mL) as well as splenomegaly, bone
marrow ﬁbrosis, and a further increase in the number of HSCs
and MkPs. Interestingly, HSCs harboring mutant CALR had no
advantage over their wild-type counterparts in transplantation
experiments,44 an observation reminiscent of results from JAK2
V617F knock-in mice.45 Studies engineering frameshift deletions
into the endogenous murine locus have typically shown a less
prominent phenotype: use of a CRISPR-Cas9 approach to
generate a 19-bp deletion in murine Calr yielded only a mild
Figure 2. In this model, disease phenotypes reﬂect, at least in part, the cytokine receptor(s) that are activated by a given driver mutation. Mutant
CALR and MPL activate MPL signaling, and so are associated with a megakaryocyte/platelet phenotype (ET or MF). By contrast, JAK2 V617F can
activate signaling via EpoR or MPL, which are associated with PV and ET/MF, respectively. The phenotype of an individual patient with a JAK2 V617Fmutation also
depends on a variety of other factors that affect EpoR or MPL signaling, including genetic background and mutation dose. JAK2 V617F also interacts with GCSFR,
probably explaining why JAK2-mutant ET patients show higher neutrophil counts than do CALR-mutant ET patients.
(2020) Vol:No www.hemaspherejournal.com
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thrombocytosis and weak activation of JAK-STAT signaling.46
Similarly, a recently published mouse model used a similar
approach to engineer a 52- or 61-bp deletion in the endogenous
mouse locus. The deletions led to increases in platelet levels of
35% and 15% respectively, with the 52-bp deletion also yielding
a slow-rising advantage in transplantation experiments. The
relatively mild phenotype could be attributed to weak activation
of murine MPL by murine mutant CALR protein.47
Together, animal studies have shown that expression of the
human type I CALR mutant C-terminus in hematopoietic cells
drives thrombocytosis and is associated with an expansion of the
HSPC compartment, though transplantation experiments suggest
these cells have no or only a slight competitive advantage.43,44 All
models show increased numbers of MKs within the bone
marrow, and some models additionally show myeloﬁbrosis at
higher levels of mutant CALR expression, whether as a
consequence of retroviral expression42 or homozygosity.44
However, some questions remain unresolved. First, why do
mouse models show no or minimal HSC advantage when human
patients typically show a clonal disease? This may be due to
varying genetic backgrounds and/or additional mutations in
patients that are not present in mouse models. In addition, aging
typically affects the microenvironment to which HSCs are
exposed, which could explain the association of MPNs with
increasing age in human patients. Finally, transplantation
experiments represent a form of stress hematopoiesis in contrast
to the steady state hematopoiesis occurring in patients. The recent
use of neutral somatic mutations as barcodes has allowed the
study of steady-state hematopoiesis in humans for the ﬁrst time48
andwill additionally permit exploration of stem cell behavior and
clonal dynamics in MPN patients. Another outstanding issue is
the inability of type II CALRmutations to render a phenotype in
animal models. While both type I and II CALR mutations are
associated with disease in humans, it is currently unknown why
only type I CALRmutant is able to drive an overt myeloprolifera-
tive phenotype in both mouse and zebraﬁsh modeling, with type
II CALR mutant described to drive mild or no thrombocytosis.
Type II mutants may be unable to bind non-human MPL or
efﬁciently activate downstream signaling.
Clinical aspects
Clinical manifestations
Both initial studies identifying CALR mutations noted a
distinct clinical picture linked with CALR lesions compared to
other driver mutations: CALR mutations were associated with
higher platelet counts, lower WBC count, lower incidence of
thrombosis, and better survival compared with JAK2 V617F
patients.1,2 Two meta-analyses and distinct cohorts of patients
later corroborated these ﬁndings.49,50 Analysis of mutations in
individual hematopoietic clones showed an early acquisition of
the lesion, compatible with an initiating event.1,2 In addition,
CALR mutations were found in patient hematopoietic stem cells
and multipotent progenitors.2 Taken together, these results agree
with previously discussed studies showing that CALR mutations
serve as a true driver of transformation.
Clinical differences have also been noted between distinct types
of CALR lesions, with type I mutations seen signiﬁcantly more
frequently in MF than in ET.1,2,4,51–53 In addition, differences in
clinical behavior have been reported between type I and type II
CALR mutations both in ET, where type II CALR mutations
were associatedwith a signiﬁcantly higher platelet count,52,54 and
in MF, where type I patients displayed a higher percentage of
circulating blasts and frequency of mutations in EZH2.3
Thrombosis is the main cause of morbidity and mortality in
MPN patients, particularly in polycythemia vera (PV) and
ET.55,56 Thrombosis incidence in CALR patients was originally
reported to be less than half of that reported in JAK2 V617F
patients.1 However, a multivariate analysis in a large cohort of
1053 ET patients showed that differences in thrombosis incidence
are not associated with the mutation per se but related to the
differences in age and history of previous thrombosis between
CALR and JAK2 V617F-mutated patients.57 This was further
conﬁrmed in a smaller cohort, where the impact of CALR
mutations on the risk of thrombosis was restricted to the group of
patients younger than sixty.58 Differences in the risk of
thrombosis between type I and II CALR mutations were
suggested in one study4 but failed to reach statistical signiﬁcance
in a larger collaborative study with 1027 patients.54 A
comparison of different leukocyte and platelet activation markers
linked with thrombosis in ET patients found no statistically
signiﬁcant differences between CALR mutated and non-mutated
patients.59
Myeloﬁbrotic transformation was reported to be signiﬁcantly
higher among CALR-mutated ET patients than JAK2 V617F
patients in one initial report.2 Follow-up studies were inconsis-
tent, some showing no increased risk of transformation,49,50 but
1 large-scale study again found a higher risk of transformation to
MF.60 Interestingly, the increase in the incidence of MF
transformation among CALR-mutated ET patients appears to
be restricted to type I mutations while patients with type II
mutations displayed no differences to JAK2 V617F patients.4
This is in agreement with a recent study on post-essential
thrombocythemia myeloﬁbrosis (PET-MF) showing a time toMF
progression signiﬁcantly longer in type II than in type I CALR
and JAK2 V617F mutations.61 As a consequence, type I
mutations were overrepresented in PET-MF while in ET the
distribution of the two most common CALR lesions was
balanced.61 Importantly, no transformation from CALR-mutat-
ed ET to PV has been reported in any of the published
cohorts.2,49,50 This stands in stark contrast to ET associated with
JAK2 mutations and may reﬂect the lack of interaction between
mutant CALR and EPOR.
Leukemic transformation was shown to be signiﬁcantly lower
in patients withCALR-mutated ET compared to those with JAK2
V617F mutated ET using a competing risk approach, but the
differences did not reach statistical signiﬁcance after adjusting for
age.49 A recent retrospective study found thatCALR-mutated ET
had a lower incidence of leukemic transformation compared to
JAK2 V617F mutation and that the leukemic risk was not
signiﬁcantly affected by myeloﬁbrotic transformation in a
multivariate analysis.62 No differences in leukemic transforma-
tion in patients with MF51,63 or leukemia-free survival64 have
been found.
Overall survival (OS) was increased inCALR-mutated patients
compared to JAK2 V617F-mutated patients after correction for
disease phenotype and the patient cohort1; this was conﬁrmed in
MF using models that also corrected for patient age.17,49 Some
reports have found a signiﬁcantly longer survival in type ICALR-
mutated MF compared to type II,3,65 while others reported
similar trends that did not reach statistical signiﬁcance.4,66 In ET
patients, no difference in OS between type I-like and type II-like
patients was reported.67 A recently published meta-analysis and
large collaborative study have conﬁrmed that CALR type I but
not type II mutations are associated with a superior overall
D. Prins et al. Mutant Calreticulin in the Myeloproliferative Neoplasms
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survival.64,68CALR- and JAK2-mutated MPNs are broadly
similar in their spectra of co-occurring mutations.69 Interestingly,
type I-like CALR mutations in MF are not only associated with
longer survival but may also correct the detrimental effect of
ASXL1 and SRSF2 mutations, typically linked to a poorer
prognosis.64,70
Overall, CALR mutations tend to be associated with a more
benign natural history compared to JAK2 V617F-mutated
disease. Differences between type I and II CALR mutations are
also seen (Table 1), but the biological basis for this difference
remains unclear.
Diagnostic approaches
CALR mutations are almost exclusively conﬁned to ET and
MF patients, though they were also identiﬁed in rare cases of
myelodysplastic syndromes (including refractory anemia with
ring sideroblasts (RARS)) and myelodysplastic-myeloprolifera-
tive syndromes.1,2 CALR point mutations have also been
described in some cases of chronic neutrophilic leukemia.72,73
Due to their role as oncogenic drivers, CALR mutations have
recently been added to the list of mutations considered major
diagnostic criteria for ET and MF in the World Health
Organization classiﬁcation of hematological malignancies.74
The screening for these mutations is part of the current diagnostic
work-up for suspected ET and MF, usually after obtaining a
negative result for the JAK2 V617F mutation.75,76 Increasing
amounts of genetic data for patients have also allowed the
classiﬁcation of MPNs based on their underlying biological
mechanisms, not solely clinical features, resulting in improved
prognostic predictions.60
As more than 50 distinctCALRmutations have been described
in ET and PMF and all of them are insertions or deletions, 2 main
molecular diagnostic strategies are currently used: Sanger
sequencing and fragment analysis, with the latter the most
practical approach in terms of sensitivity and efﬁciency.77 Other
alternative methods have been proposed, including high resolu-
tion melting curve analysis and real-time PCR, but these
techniques have been validated for only the two most frequent
mutations and offer only modest sensitivity improvements over
fragment analysis.78 Next generation sequencing (NGS) strate-
gies are quite attractive since the detection of additional
mutations in MPN has a proven prognostic value. However,
accurate indel variant calling is still challenging and distinguish-
ing them from technical errors remains difﬁcult.79,80
Treatment
The treatment goals for ET and MF patients are the same
irrespective of the driver mutation: controlling the symptoms and
extending the lifespan of the patients by reducing their
thrombohemorrhagic risk. In ET, young patients without
thrombotic risk factors generally beneﬁt from thromboprophy-
laxis with low dose aspirin, while the combination of low dose
aspirin and hydroxycarbamide signiﬁcantly reduces the incidence
of thrombosis in patients older than 60 years or with a previous
thrombosis.56,81,82 Other available cytoreductive agents such as
anagrelide56 or interferon alfa83,84 are used as second line options
in speciﬁc cases, including young or pregnant patients requiring
cytoreduction.
MF presents with a progressive clinical picture, ranging from
the absence of symptoms to anemia, splenomegaly, constitutional
symptoms, or transformation to acute myeloid leukemia. In
contrast to ET, patients with MF tend to have a substantially
reduced lifespan. However, the only curative treatment currently
available for MF is allogeneic stem cell transplant. The current
guidelines therefore recommend a symptom- and risk-based
approach: although most patients are treated symptomatically,
higher-risk and otherwise ﬁt patients may be recommended for
stem cell transplant. Management of symptoms include erythro-
poiesis-stimulating agents or danazol for anemia; hydroxycar-
bamide for splenomegaly, thrombocytosis, and leucocytosis; and
ruxolitinb or fedratinib for splenomegaly and constitutional
symptoms. Ruxolitinib and febratinib, both non-speciﬁc JAK
inhibitors, exert their therapeutic effects through the down-
regulation of pro-inﬂammatory cytokines,85,86 which is partially
mediated via JAK1 inhibition.87
Current recommendations for ET andMF are based on clinical
trials conducted prior to the discovery of CALR or JAK2 V617F
mutations.56,75,76,81,82,88 Nevertheless, as explained above,
CALR-mutated patients have some distinct clinical character-
istics and could potentially beneﬁt from a more tailored
management. For instance, in a recently published retrospective
study in low risk ET patients, low-dose aspirin was not only
unable to reduce risk of thrombosis but was also associated with
an increased risk of hemorrhage.71 However, most guidelines
consider that this is not enough evidence to recommend
withholding aspirin in CALR-mutated ET before these results
are conﬁrmed by clinical trials.75,76 In addition to response to
antiplatelet therapy, time free from cytoreduction is also shorter
in CALR-mutated ET than in JAK2-mutated ET, usually because
of extreme thrombocytosis in the former.71
Most patients diagnosed with CALR-mutated MPN have a
satisfactory management with current antiplatelet and cytor-
eductive therapies, though some MF patients fail to respond to
the currently available therapy. CALR mutation status does not
signiﬁcantly inﬂuence the outcome of treatment with ruxolitinib,
as shown by retrospective analysis of CALR-mutated patients
in the COMFORT-II trial.89 In contrast, CALR mutations,
particularly type I, are associated with a better overall survival
and spleen response in patients treated with momelotinib, a
JAK1/2 inhibitor.90,91 Similarly, CALR mutations were found to
be an independent factor for lower non-relapse mortality (NRM),
improved progression free survival (PFS), and OS following
allogenic bone marrow transplant in patients with MF, despite
the large proportion of CALR-positive patients with intermedi-
ate-high and high risk scores at the time of transplantation.92 In
another series of patients, those with CALR mutations were
found to have a higher probability of clearing the minimal
residual disease after transplant as compared to JAK2V617F and
MPL-mutated patients93; this is regarded as a strong predictor of
PFS.94,95 This is in line with recent ﬁndings that type I-like CALR
mutations independently predict a better outcome in allogeneic
Table 1
Clinical Differences Between CALR and JAK2 V617F Mutations.
CALR vs JAK2 V617F mutations Type I vs type II CALR mutations
CALR found in ET and MF only; JAK2
V617F found in ET, MF, and PV
Higher platelet count (for CALR)
Lower WBC count
Lower incidence of thrombosis
Higher incidence of aspirin-induced
haemorrhage71
Longer survival in MF
Lower age at presentation (for type I)
Lower platelet count
Overrepresentation in MF
Higher incidence of PET-MF
Longer survival in MF
(2020) Vol:No www.hemaspherejournal.com
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bone marrow transplants, leading to the inclusion of type I-like
CALR mutations as an independent variable in MIPSS70, a
prognostic system for transplantation in patients with MF.96
There has also been interest in exploiting mutant CALR
antigenicity as a target for cancer immunotherapy.97,98 Cultured
CD4+ T-cells from a patient with mutated CALR were able to
recognize and kill autologous CD34+ HSCs, leading the authors
to speculate that vaccinating patients with mutant CALR
epitopes could induce the immune system to eliminate muta-
tion-bearing HSCs.98 A further analysis of mutant CALR
associated neo-antigens identiﬁed a subset of potential interest
for immunotherapy.99
Future directions
In the 6 years since the ﬁrst description of CALR mutations in
ET andMF patients, signiﬁcant insight has been gained into their
biochemical and cell biological consequences and their clinical
implications. It is clear that the primary mechanism of CALR-
driven transformation lies in its interaction with MPL, which
triggers JAK2-dependent signaling pathways, although it remains
to be seen whether mutant CALR may also act through other
pathways, such as Ca2+ signaling or transcriptional regulation.
Mouse models ofCALRmutations consistently exhibit ET and
MF-like phenotypes and can be used in the development of new
targeted therapies. These models also raise new questions
concerning the fundamental biology of CALR mutations. First,
while both type I and type II mutations are associatedwith disease
in humans and produce autonomous cell growth in several cell
lines, only the former give rise to a consistent thrombocytosis
phenotype in mice. Secondly, in contrast to ET and MF patients,
CALRmutations do not confer a strong competitive advantage to
HSCs. Further exploration of these intriguing observations will
serve to illuminate the mechanisms by which CALR mutations
cause disease.
Improved technologies and decreasing costs of sequencing
have led to the generation of a wealth of genomic data on patients
with MPNs. A knowledge bank approach has revealed a new
genomic classiﬁcation of the MPNs based on their underlying
biological causes and has also allowed the development of
personalized prognoses for individual patients.60 Furthermore,
single-cell approaches tracking somatic mutations are now being
used in humans to examine clonal dynamics in healthy, steady-
state hematopoiesis. Extension of these techniques to hemato-
poiesis in MPN, particularly at multiple time points through
disease progression and treatment, will further illuminate the
mechanisms underlying these diseases.
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